Market Overview

Three IPOs Hit Wall Street on February 12

Related EGRX
The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
Related TLMR
Benzinga's Top Upgrades
Benzinga's Volume Movers

Since new Federal Reserve Chairman, Janet Yellen, has taken control, the Dow Jones Industrial Average has skyrocketed, and IPOs averaged up about five percent on Wednesday. Investors and traders are looking for more opportunities in the IPO market.

IPOs generally increase as they publicly debut on their respective stock index. Three prominent companies started to publicly trade their index on February 12.

Eagle Pharmaceuticals (NASDAQ: EGRX) is a specialty pharmaceutical that develops and commercializes injectables products. This company is very to other prominent companies in this space. Eagle Pharmaceuticals priced public at $15.00 at 3.35 million shares. In addition, Eagle has granted its respective underwriters an exclusive 30-day option to buy another 502,500 shares of common stock.

Talmer Bancorp (NASDAQ: TLMR) is the holding company for two banks, which operate 94 branches. Talmer opened Wednesday morning at $13.75 after it had originally priced at 15.5 million shares. It priced at 13.00, and luckily for shareholders, Talmer has continued to move higher.

Flexion Therapeutics (NASDAQ: FLXN) shares opened at $16.00 per share, after they had originally priced at $13.00 at five million shares. Like Eagle, Flexion specializes in developing and commercializing injectables pain therapies.

Posted-In: News IPOs


Related Articles (FLXN + EGRX)

View Comments and Join the Discussion!

Mid-Day Market Update: U.S. Stocks Rise; Orbitz Shares Surge On Upbeat Results

Top Financial Tweets From February 13, 2014